Protease Inhibition-An Established Strategy to Combat Infectious Diseases

0555025 - BC 2022 RIV CH eng J - Článek v odborném periodiku
Sojka, Daniel - Šnebergerová, Pavla - Robbertse, Luise
Protease Inhibition-An Established Strategy to Combat Infectious Diseases.
International Journal of Molecular Sciences. Roč. 22, č. 11 (2021), č. článku 5762. E-ISSN 1422-0067
Grant CEP: GA ČR(CZ) GA20-05736S; GA MŠMT(CZ) EF16_019/0000759
Institucionální podpora: RVO:60077344
Klíčová slova: plasmodium-falciparum * plasmepsin-v * malaria parasites * drug discovery * potent * validation * proteins * invasion * egress * target * protease * parasites * inhibition * therapy * infectious diseases
Obor OECD: Immunology
Impakt faktor: 6.208, rok: 2021
Způsob publikování: Open access
https://www.mdpi.com/1422-0067/22/11/5762

Therapeutic agents with novel mechanisms of action are urgently needed to counter the emergence of drug-resistant infections. Several decades of research into proteases of disease agents have revealed enzymes well suited for target-based drug development. Among them are the three recently validated proteolytic targets: proteasomes of the malarial parasite Plasmodium falciparum, aspartyl proteases of P. falciparum (plasmepsins) and the Sars-CoV-2 viral proteases. Despite some unfulfilled expectations over previous decades, the three reviewed targets clearly demonstrate that selective protease inhibitors provide effective therapeutic solutions for the two most impacting infectious diseases nowadays-malaria and COVID-19.
Trvalý link: http://hdl.handle.net/11104/0329643